文献速递其他结缔组织病

血管化人皮肤等效模型:皮肤纤维化体外新模型及抗纤维化药物测试平台

Vascularised human skin equivalents as a novel in vitro model of skin fibrosis and platform for testing of antifibrotic drugs.
PubMed 文献 · Ann Rheum Dis · 2019-09-20

该研究在三维细胞外基质上依次接种内皮细胞、成纤维细胞和角质形成细胞,构建血管化人皮肤等效模型,并在生理压力下灌注形成成熟极化表皮、分层真皮和功能性血管系统。暴露于TGFβ后,模型再现了系统性硬化症皮肤的关键特征,包括TGFβ通路激活、成纤维细胞向肌成纤维细胞转化、胶原释放增加和细胞外基质过度沉积;尼达尼布治疗可改善这种纤维化转化。

要点

  • 血管化人皮肤等效模型在生理压力灌注下形成成熟极化表皮、分层真皮和功能性血管系统。
  • TGFβ暴露可再现系统性硬化症皮肤纤维化的关键特征。
  • 尼达尼布可改善该模型中的纤维化转化,提示其可作为抗纤维化药物测试平台。

核心结论

  • 血管化皮肤等效模型可复制纤维化皮肤的关键特征,并可能作为在病理生理相关人类环境中评估抗纤维化药物的平台。

研究设计与样本

  • 在三维细胞外基质上依次接种内皮细胞、成纤维细胞和角质形成细胞组装皮肤等效模型,并在生理压力下灌注。

主要发现

  • 皮肤等效模型在生理压力灌注下形成成熟极化表皮、分层真皮和功能性血管系统。
  • 暴露于TGFβ后,模型再现了系统性硬化症皮肤的关键特征:TGFβ通路激活、成纤维细胞向肌成纤维细胞转化、胶原释放增加和细胞外基质过度沉积。
  • 尼达尼布治疗可改善TGFβ诱导的纤维化转化。

临床怎么用

  • 该模型可用于在人类相关体外系统中评估抗纤维化药物对皮肤纤维化的作用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Fibrosis is a complex pathophysiological process involving interplay between multiple cell types. Experimental modelling of fibrosis is essential for the understanding of its pathogenesis and for testing of putative antifibrotic drugs. However, most current models employ either phylogenetically distant species or rely on human cells cultured in an artificial environment. Here we evaluated the potential of vascularised in vitro human skin equivalents as a novel model of skin fibrosis and a platform for the evaluation of antifibrotic drugs. METHODS: Skin equivalents were assembled on a three-dimensional extracellular matrix by sequential seeding of endothelial cells, fibroblasts and keratinocytes. Fibrotic transformation on exposure to transforming growth factor-β (TGFβ) and response to treatment with nintedanib as an established antifibrotic agent were evaluated by quantitative polymerase chain reaction (qPCR), capillary Western immunoassay, immunostaining and histology. RESULTS: Skin equivalents perfused at a physiological pressure formed a mature, polarised epidermis, a stratified dermis and a functional vessel system. Exposure of these models to TGFβ recapitulated key features of SSc skin with activation of TGFβ pathways, fibroblast to myofibroblast transition, increased release of collagen and excessive deposition of extracellular matrix. Treatment with the antifibrotic agent nintedanib ameliorated this fibrotic transformation. CONCLUSION: Our data provide evidence that vascularised skin equivalents can replicate key features of fibrotic skin and may serve as a platform for evaluation of antifibrotic drugs in a pathophysiologically relevant human setting.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Matei AE, Chen CW, Kiesewetter L, et al. Vascularised human skin equivalents as a novel in vitro model of skin fibrosis and platform for testing of antifibrotic drugs. Ann Rheum Dis. 2019. PMID: 31540936. doi:10.1136/annrheumdis-2019-216108

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。